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Original Paper
Anxiolytic-like effect of oxytocin in the
simulated public speaking test
Danielle CG de Oliveira1, Antonio W Zuardi1,2, Frederico G Graeff1,
Regina HC Queiroz2,3 and Jose´ AS Crippa1,2
Abstract
Oxytocin (OT) is known to be involved in anxiety, as well as cardiovascular and hormonal regulation. The objective of this study was to assess the acute
effect of intranasally administered OT on subjective states, as well as cardiovascular and endocrine parameters, in healthy volunteers (n¼ 14)
performing a simulated public speaking test. OT or placebo was administered intranasally 50 min before the test. Assessments were made across
time during the experimental session: (1) baseline (30 min); (2) pre-test (15 min); (3) anticipation of the speech (50 min); (4) during the speech
(1:03 h), post-test time 1 (1:26 h), and post-test time 2 (1:46 h). Subjective states were evaluated by self-assessment scales. Cortisol serum and plasma
adrenocorticotropic hormone (ACTH) were measured. Additionally, heart rate, blood pressure, skin conductance, and the number of spontaneous
fluctuations in skin conductance were measured. Compared with placebo, OT reduced the Visual Analogue Mood Scale (VAMS) anxiety index during the
pre-test phase only, while increasing sedation at the pre-test, anticipation, and speech phases. OT also lowered the skin conductance level at the pre-
test, anticipation, speech, and post-test 2 phases. Other parameters evaluated were not significantly affected by OT. The present results show that OT
reduces anticipatory anxiety, but does not affect public speaking fear, suggesting that this hormone has anxiolytic properties.
Keywords
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Introduction
Oxytocin (OT) is a nonapeptide synthesized in the paraven-
tricular and supraoptic nuclei of the hypothalamus. OT is
transported in vesicles from the magnocellular nuclei of
the supraoptic and paraventricular nuclei to the neurohy-
pophysis, where it is stored and then released into the blood-
stream. OT is also present in the central nervous
system, where it originates from both the parvocellular
and magnocellular neurons after dendritic local release
(Bujis, 1978; Landgraf and Neumann, 2004; Ludwig et al.,
2002).
OT has both peripheral endocrine and central neural
actions. Its peripheral actions on lactation and parturition
have long been established. Centrally, it has been suggested
that OT acts as a neurotransmitter or neuromodulator regu-
lating neuroendocrine, behavioral and autonomic responses
to stress. Thus, it has been reported that OT administration
attenuates glucocorticoid secretion (Ditzen et al., 2009;
Heinrichs et al., 2003; Neumann, 2002; Neumann et al.,
2000; Windle et al., 1997) and stress-induced increases in arte-
rial pressure (Holst et al., 2002; Windle et al., 1997). In addi-
tion, OT had anxiolytic-like eﬀects in both male (Ring et al.,
2006; Waldherr et al., 2007) and female rats (Bale et al., 2001;
Neumann et al., 2000; Windle et al., 1997) and mice
(McCarthy et al., 1996; Mantella et al., 2004). Accordingly,
Mantella et al. (2003) have shown that female OT knockout
mice were more anxious than wildtype controls, an eﬀect that
was reversed by the central administration of OT. In addition,
control mice showed increased anxiety after administration of
an OT receptor antagonist. So far, studies in humans are
scarce, but preliminary data suggest that intranasally admin-
istered OT has an anxiolytic-like eﬀect (Heinrichs et al.,
2003).
OT has also been shown to be involved in the regulation of
social behavior. In monogamous female prairie voles
(Microtus ochrogaster), OT is believed to participate in
bond formation between couples, since this bonding is inhib-
ited by a selective OT receptor antagonist (Insel and Hulihan,
1995; Williams et al., 1994). In humans, two recent studies
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used functional magnetic resonance imaging to assess the
eﬀect of OT on activation of the amygdala during recognition
of emotional faces and in response to non-social stimuli
(Domes et al., 2007; Kirsch et al., 2005). In the ﬁrst study,
the results showed decreased amygdala activation in response
to negative social and non-social stimuli when OT was admin-
istered, relative to baseline. These results may explain why OT
attenuates stress and anxiety in rodents and humans (Herman
and Cullinan, 1997). The second study, which involved only
social stimuli of positive and negative emotions, showed that
OT attenuates the response of the amygdala relative to pla-
cebo, regardless of stimulus valence. OT attenuates negative
aﬀective evaluations associated with aversively conditioned
faces through modulation of the amygdala and fusiform
gyrus in non-clinical adults (Petrovic et al., 2008). The par-
ticipation of OT in the modulation of social behaviour has
been strongly supported by the recent discovery of the trans-
membrane receptor CD38, which seems to be involved in
maternal behavior and social recognition by regulation of
OT secretion (Jin et al., 2007). These results indicate the
need for further studies on OT and anxiety, especially social
anxiety.
Epidemiological studies have revealed that the fear of
public speaking is highly prevalent among students (Geer,
1965), regardless of gender, ethnic origin or age (Phillips
et al., 1997). In addition, public speaking is the most
common type of social fear (Furmark et al., 1999; Stein
et al., 1994) and is also one of the major symptoms of
social phobia (Brunello et al., 2000; Stein et al., 1996). For
these reasons, and to obtain a clinical model of anxiety,
McNair et al. (1982) developed the Simulated Public
Speaking Test (SPST). This model, later modiﬁed by
Guimara˜es et al. (1987), induces anxiety in healthy subjects
and can detect anxiolytic or anxiogenic eﬀects of drugs
(Guimara˜es et al., 1987; Palma et al., 1994; Zuardi et al.,
1993). The objective of the present study was to measure
the eﬀect of OT administered intranasally on subjective and
psychophysiological changes induced by the SPST in healthy
young male volunteers.
Materials and methods
Subjects
The study was conducted on 28 healthy male volunteers, who
were randomly assigned to receive intranasal administration
of OT (Syntocinon, Novartis, Brazil) or placebo
(Syntocinon vehicle, Novartis). The groups were matched
for age, body mass index, personal and parental socioeco-
nomic level, anxiety level and intensity of fear of public speak-
ing, as shown in Table 1. Exclusion criteria were: use of
any concomitant medication; history of neurological disease;
psychiatric disorders; renal, pulmonary, hepatic or cardiovas-
cular problems; hypertension; smoking; alcoholism; and
abusive drug use. Subjects were instructed not to eat or
drink (except water) for 2 h before the experiment and not
to engage in exercise or ingest alcoholic or caﬀeinated
drinks for a period of 24 h before the experiment. Subjects
were blinded to treatment condition until the end of the
experiment. All subjects received detailed information
about the research and were included in the study after
giving written informed consent. The study was approved
by the local Ethics Committee.
Screening procedure
The intensity of fear of public speaking was evaluated by
the State version of the Self Statement of Public Speaking
(SSPS-S) scale (Hofmann and Dibartolo, 2000). To exclude
the possibility of harmful use of alcohol, only subjects with a
score of less than 3 on the Fast Alcohol Screening
Test (FAST) scale were included (Hodgson et al., 2002).
To exclude the possible presence of any psychiatric disor-
der, the short version of the Patient Health Questionnaire
(PHQ-2) (Kroenke et al., 2003) and Self-Reporting
Questionnaire (SRQ) (Mari and Williams, 1985) scales were
used for initial screening, followed by later application of the
Portuguese version (Del-Ben et al., 2001) of the structured
clinical interview for the DSM-IV (SCID-IV) (First et al.,
1997) by a qualiﬁed psychiatrist. The socioeconomic class of
the subjects and their parents was determined using
the Criteria of Socioeconomic Classiﬁcation for Brazil
(CCSEB, 1997).
Oxytocin administration
OT (Syntocinon Nasal Spray, Novartis) or placebo
(Syntocinon vehicle, Novartis) was administered intrana-
sally in a single dose of 24 IU in three applications of 4 IU
per nostril. This dose was selected based on previous
reports demonstrating an anxiolytic eﬀect (Heinrichs et al.,
2003; Kosfeld et al., 2005) and the presence of OT in
Table 1. Characteristics of the study groups
Treatment
Oxytocin (n¼ 14) Placebo (n¼ 14)
Variables Mean6 SD Mean6 SD p-value
Age (years) 23.86 2.4 23.66 3.1 0.8
BMI 25.16 4.4 24.26 4.3 0.6
SSPS-S 38.36 8.1 37.76 4.7 0.8
BAI 10.56 8.1 10.66 8.7 0.9
BAI: Beck Anxiety Inventory, BMI: body mass index (kg/m2), SSPS-S: State version of the Self Statement of Public Speaking scale
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the cerebrospinal ﬂuid after intranasal administration
(Born et al., 2002).
Measures
Psychological measures. The following self-evaluation
scales were used for the assessment of subjective states
during SPST. (1) The Visual Analogue Mood Scale (VAMS)
was created by Norris (1971) and translated and validated for
Portuguese by Zuardi and Karniol (1981). The 16 items are
grouped into four factors: anxiety, sedation, cognitive impair-
ment, and discomfort (Parente et al., 2005). (2) The Bodily
Symptoms Scale (BSS) (Zuardi et al., 1993) was used to eval-
uate somatic symptoms that may indirectly aﬀect anxiety.
The scale consists of 21 items on which the subjects indicate
how they feel at the time, ranging from not at all (0) to
extreme (5). (3) The State version of the Self-Statements
during Public Speaking (SSPS) scale, used to evaluate fear
of public speaking, consists of 10 items that can be divided
into positive self-evaluation (items 1, 3, 5, 6 and 9) and neg-
ative self-evaluation (items 2, 4, 7, 8 and 10). The subjects
must assign scores ranging from 0 (totally disagree) to 5
(totally agree) on each item (Hofmann and Dibartolo, 2000;
Oso´rio et al., 2008).
Physiological and psychophysiological measures. The
following physiological and psychophysiological measure-
ments were assessed: (1) arterial blood pressure, including
systolic and diastolic blood pressure, were measured using a
mercury sphygmomanometer (Becton Dickinson, Brazil); (2)
heart rate was estimated by pulse rate; (3) skin conductance
was measured using a computer-controlled, voltage-constant
(0.6V) module with automatic back oﬀ (Contact Precision
Instruments, UK). Two electrodes (Beckman, UK) were
ﬁxed with adhesive tape to the ﬁngers with skin contact
made through high conductance gel (KY gel, Johnson and
Johnson, Brazil). Both skin conductance (SC) and the
number of spontaneous ﬂuctuations in skin conductance
(SFSC) were recorded.
Hormonal measures. Blood was collected at scheduled
times while the subject was seated, and 10mL from each
time point was immediately transferred to polypropylene
tubes. Samples used to assay adrenocorticotropic hormone
(ACTH) used EDTA as an anticoagulant. Samples used for
cortisol measurement were transferred to tubes containing
separating gel. All tubes were kept on ice during the experi-
mental session. Blood samples for both ACTH and cortisol
assessment were centrifuged at 3000 rpm for 15min at 48C,
and plasma and serum aliquots were stored in polypropylene
tubes at 208C until analysis.
Procedure
The SPST was conducted as described by McNair et al. (1982)
using modiﬁcations by Guimara˜es et al. (1987). The experi-
mental session was performed in a sound-attenuated room
with controlled temperature. After a 15-min period of
adaptation to the laboratory environment, the ﬁrst informed
consent form was presented for signature, and initial mea-
surements (Baseline) were performed, followed by administra-
tion of OT or placebo. At this time, subjects were catheterized
for later collection of blood. After 36min without stimula-
tion, pre-test measurements (Pre-test) were acquired.
Immediately thereafter, subjects viewed a videotape contain-
ing instructions about the task. Subjects were instructed that
they would have 2min to prepare a 4-min speech about local
public transportation. This topic was selected as an emotion-
ally neutral topic requiring common knowledge. Subjects
were instructed that they would be interrupted during their
talk for the administration of scales and that the speech
would be recorded on videotape and later analyzed by a psy-
chologist. At this time, the second informed consent form was
presented for signature. If the subject agreed to continue,
measurements of the subject’s states during speech prepara-
tion (Anticipation) were taken. Next, subjects began to deli-
ver their speech in front of a video camera while viewing their
own images on the screen. The speech was interrupted
after 2min so that subjective measurements of performance
anxiety (Speech) could be taken. Post-stress measurements
were made 15min (Post-test 1) and 20min (Post-test 2) after
the end of the speech. Each volunteer participated in only one
experimental session. Table 2 shows the timeline of the
procedures.
Data analysis
The results obtained for the 16 items of the VAMS were
divided into four factors according to their relative weights:
anxiety, sedation, cognitive impairment, and discomfort
(Zuardi et al., 1993). The VAMS, SSPS, heart rate, blood
pressure (systolic and diastolic), SC and SFSC data were eval-
uated using a mixed eﬀects linear model for each dependent
variable (Gueorguieva and Krystal, 2004) with time and
group as ﬁxed eﬀects and subject as a random eﬀect.
This procedure is adequate when data are correlated, as
each response is inﬂuenced by the preceding response.
The individual items of the BSS were analyzed by the
Kruskal–Wallis test. The possible association between group
and social class and group comparisons for discrete vari-
ables were analyzed by chi-square tests. SAS software version
9 was used for statistical analysis with the level of signiﬁcance
set at p< 0.05.
Results
Psychological measures
VAMS. The eﬀects of oxytocin on VAMS anxiety and seda-
tion factors are shown in Figure 1. Intragroup analyses
showed that public speaking was associated with an increase
in anxiety in both OT and placebo groups. In the placebo
group, anxiety was increased during Anticipation compared
with Baseline (p< 0.05) and Pre-Test (p< 0.01), followed by a
decrease at Post-Test 1 (p< 0.001) and Post-Test 2 (p< 0.001)
compared with Anticipation. Anxiety was also higher in the
Speech phase compared with Pre-test (p 0.01), Post-test 1
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(p< 0.01) and Post-test 2 (p< 0.01). In the OT group, anxiety
was higher in the Anticipation phase than Pre-test (p 0.001).
In addition, there was a signiﬁcant decrease in anxiety in the
Pre-test phase compared with Baseline (p 0.01). Intergroup
comparisons at each phase showed that the OT group had a
lower level of anxiety than the placebo group at Pre-test
(p< 0.05), indicating that OT decreased anxiety before, but
not during, the public speaking test.
As expected, public speaking reduced sedation. In the pla-
cebo group, intragroup comparisons showed that sedation
was lower in the Anticipation phase than at Baseline
(p< 0.001), Pre-test (p< 0.001), Post-test 1 (p< 0.001) and
Post-test 2 (p< 0.001). Sedation in the Speech phase was
also lower than at Baseline (p< 0.01), Pre-test (p< 0.01),
Post-test 1 (p< 0.01) and Post-test 2 (p< 0.001). In the OT
group, sedation was lower in the Anticipation phase com-
pared with Baseline (p< 0.01) and Pre-test (p< 0.001).
Sedation was also lower in the Speech phase compared with
Baseline (p< 0.05) and Pre-test (p< 0.001). Intergroup com-
parisons at each phase showed that sedation was
higher in the OT group than in the placebo group in the
Pre-test (56.76 2.0mm; 47.56 2.5mm, p¼ 0.003),
Anticipation (47.16 1.7mm; 39.06 2.9mm, p¼ 0.01) and
Speech phases (47.76 1.3mm; 41.06 3.0mm, p¼ 0.02), indi-
cating that OT increased sedation before and during public
speaking.
Table 2. Timeline of the experimental Simulated Public Speaking Test session
Time Phase Procedure
0:30 Adaptation Arrival at laboratory; first consent form
0:15 Baseline (B) measures VAMS, SSPS-S, BSS, SC, SFSC, HR, SBP, DBP, blood collection
0:00Drug administration Oxytocin or placebo administration
0:36Pre-test (Pre) VAMS, SSPS-S, BSS, SC, SFSC, HR, SBP, DBP, blood collection
0:46 Instructions Subjects instructed via videotape to prepare a speech on the transport system; second consent form
0:48Speech preparation Subjects prepare speech
0:50Anticipation (A) measures VAMS, SSPS-S, BSS, SC, SFSC, HR, SBP, DBP, blood collection
1:01Beginning of speech Subjects deliver speech while watching themselves on video camera screen
1:03Speech-induced performance anxiety (S)VAMS, SSPS-S, BSS, SC, SFSC, HR, SBP, DBP
1:09Middle of speech Subjects continue to deliver speech
1:11End of speech Blood collection
1:26Post-test 1 (P1) VAMS, SSPS-S, BSS, SC, SFSC, HR, SBP, DBP
1:36Plasma determinations Blood collection
1:46Post-test 2 (P2) VAMS, SSPS-S, BSS, SC, SFSC, HR, SBP, DBP
1:56Plasma determinations Blood collection
Tests began at 08:00. BSS: Bodily Symptoms Scale, DBP: diastolic blood pressure, HR: heart rate, VAMS: Visual Analogue Mood Scale, SBP: systolic blood pressure, SC: skin
conductance, SFSC: spontaneous fluctuations in skin conductance, SSPS-S, State version of the Self Statement of Public Speaking scale
Figure 1. Changes in anxiety and sedation factors induced by a simulated public speaking task, measured in 28 healthy male volunteers who received
oxytocin or placebo (n¼ 14/group). Scales were applied at different phases of the experimental session: baseline (B), pre-test (PT), anticipation of the
speech (Pr), during the speech (S), post-test 1 (F1), and post-test 2 (F2). Data are reported as means6 SEM. *p< 0.05 relative to placebo.
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Intragroup and intergroup comparisons showed no statis-
tically signiﬁcant diﬀerence among the various phases and
groups regarding the cognitive impairment and discomfort
factors of the VAMS, as shown in Table 3.
BSS. The OT group showed greater lethargy (item 3) in the
Speech and Post-test 1 phases (p< 0.05). In addition, the pla-
cebo group showed more palpitation (item 11) in the Pre-test
and Speech phases (p< 0.05).
SSPS. There were no signiﬁcant group diﬀerences observed
during the various phases of positive or negative self-evalua-
tion of public speaking.
Physiological and psychophysiological measures
The eﬀect of oxytocin on skin conductance is shown in
Figure 2. OT lowered the SC in the Pre-test, Anticipation,
Speech and Post-test 2 phases (p< 0.05). No signiﬁcant
diﬀerences were detected for the other variables, as shown
in Table 4.
Hormonal measures
Intergroup comparisons of cortisol and ACTH showed no
signiﬁcant diﬀerences between the various phases.
Discussion
The present results show that the SPST increased VAMS anx-
iety in both treatment groups, as revealed by a signiﬁcant
increase of anxiety from the Pre-test to the Anticipation
phase, supporting previous ﬁndings (Graeﬀ et al., 2003).
However, the OT group showed a signiﬁcant reduction of
anxiety from the Baseline to the Pre-test phase, suggesting
that OT facilitates habituation of anticipatory anxiety. This
hypothesis is supported by the signiﬁcant diﬀerence between
OT and placebo groups at the Pre-test phase. This reduction
of anxiety during the Pre-test phase compared with Baseline
and with placebo was similar to the eﬀect of diazepam, which
has also been shown to lower anxiety levels during the Pre-
test phase (Zuardi et al., 1993). Neither OT nor diazepam was
able to reduce the increase in anxiety generated by pub-
lic speaking (Anticipation and Speech phases), indicating
that this is a diﬀerent type of anxiety from anticipatory anx-
iety. In contrast, results have shown that drugs that act pri-
marily on serotinergic neurotransmission do not aﬀect
anxiety during the Pre-test phase, but either reduce or
increase anxiety in the Anticipation and Speech phases
(Graeﬀ et al., 2003). The sedation data support the idea of
an anxiolytic action of OT similar to that of the benzodiaze-
pines, which show greater sedation during the Pre-test,
Anticipation and Speech phases in the OT group relative to
controls. Diazepam and oxytocin have been shown to exert
anxiolytic eﬀects in the same experimental paradigms.
Recently, an electrophysiology study showed that oxytocin
can facilitate the eﬀects of diazepam in the amygdala
(Viviane et al., 2010).
McNaughton and Corr (2004) have proposed that the
same set of longitudinally organized brain structures, located
in the midbrain and frontal cortex, govern anxiety and fear.
They suggest that, while both midbrain and forebrain areas
are involved in anxiety and fear, the more rostral areas, such
Table 3. Changes in Visual Analogue Mood Scale (VAMS) factors induced by the Simulated Public Speaking Test
Anxiety Sedation Cognitive impairment Discomfort
Phase OT PL OT PL OT PL OT PL
Baseline 52.46 2.3 54.06 2.5 52.86 1.7 47.36 1.7 51.66 1.6 49.16 1.7 48.06 1.1 45.26 2.0
Pre-test 46.56 2.0* 52.76 1.9 56.76 2.0* 47.56 2.5 51.86 1.2 51.26 1.0 49.76 0.9 46.56 1.5
Anticipation 54.16 1.6 59.36 2.6 47.16 1.7* 39.06 2.9 51.36 0.8 51.36 1.2 48.86 0.7 46.66 1.3
Speech 54.56 1.9 58.46 2.7 47.76 1.3* 41.06 3.0 49.96 0.6 51.36 1.7 49.36 0.5 46.26 1.4
Post-test 1 51.06 1.8 51.16 1.2 51.06 1.5 46.76 2.4 50.86 0.5 49.96 1.3 49.96 0.9 47.26 1.0
Post-test 2 51.76 1.6 50.96 1.5 49.46 1.5 48.36 1.9 50.56 0.5 50.16 1.6 48.86 1.4 47.86 1.1
Data are reported as means6 SEM. OT: oxytocin, PL: placebo. *p< 0.05 relative to placebo
Figure 2. Changes in electrical skin conductance induced by a simulated
public speaking task at different phases of the experimental session:
baseline (B), pre-test (PT), anticipation of the speech (Pr), during the
speech (S), post-test 1 (F1), and post-test 2 (F2). Data are reported as
means6 SEM. *p< 0.05 relative to placebo.
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as the prefrontal cortex and the amygdala, would predomi-
nantly control anxiety, whereas the more caudal structures,
such as the hypothalamus and midbrain periaqueductal
gray matter, would predominantly control fear and panic.
Defensive distance is likely to be a key factor, since a func-
tional neuroimaging study in humans has shown that neural
activation shifts from the prefrontal cortex to the periaque-
ductal gray matter as threat becomes more imminent
(Mobbs et al., 2007). Thus, based on the responses observed
to diﬀerent types of drugs, it may be assumed that in the
SPST anticipatory anxiety occurs from the beginning to
the pre-test phase, and fear of public speaking occurs in the
speech preparation/anticipation and performance phases
(Graeﬀ et al., 2003). Among the brain structures involved in
defense, OT receptors have been detected in the amygdala
(Condes-Lara et al., 1994; Kremarik et al., 1993; Mantella
et al., 2003), septum (Insel et al., 1993; McCarthy et al.,
1996; Mantella et al., 2003), hippocampus, and hypothalamus
(Blume et al., 2008; Mantella et al., 2003; Sofroniew, 1983). In
particular, a signiﬁcant activation of the oxytocinergic system
in the central amygdala in response to swim stress suggests
that OT receptor-mediated mechanisms within the amygdala
are involved in the generation of passive stress-coping strate-
gies (Ebner et al., 2005). These ﬁndings were partially con-
ﬁrmed in humans in an fMRI study, which showed that OT
modulates the expression of evaluative conditioning for
socially relevant faces via inﬂuences on amygdala and fusi-
form gyrus, which may explain the prosocial eﬀects of OT
(Petrovic et al., 2008). With the exception of the hypothala-
mus, where oxytocin exerts hormonal functions and has anxi-
olytic eﬀects mediated by local OT receptor-induced
activation of the ERK½ cascade (Blume et al., 2008), rostral
structures are primarily involved in anxiety rather than fear
(McNaughton and Corr, 2004). In contrast, OT receptors in
the midbrain periaqueductal gray matter (Ogawa et al., 1992)
are likely involved in fear, as this structure is thought to be
activated in panic attacks (Graeﬀ, 2004).
The present results show that oxytocin failed to reduce
fear of public speaking, the most feared social situation.
This was unexpected in view of previously reported evidence
suggesting that OT promotes social facilitation (Insel and
Hulihan, 1995; Williams et al., 1994). For instance,
Heinrichs et al. (2003) found anxiolytic eﬀects of intranasal
oxytocin (24 IU) using the Trier Social Stress Test (TSST)
(Kirschbaum et al., 1993), which primarily consists of a
public speaking task and mental arithmetic performed in
front of an audience. The authors also observed that the com-
bination of oxytocin and social support exhibited the lowest
cortisol concentrations, as well as increased calmness and
decreased anxiety during stress. Nevertheless, it is possible
that doses above the range used in the current study could
be eﬀective. Higher doses should therefore be investigated,
especially in patients with social anxiety disorder.
An anxiolytic action of OT is supported by the pre-
sent study, showing lower results for SC in the OT group
during the Pre-test, Anticipation, Speech and Post-test
2 phases. Fowles (1980, 2000) suggested that SC is involved
in anticipatory anxiety, whereas changes in SFSC and
heart rate, which were not aﬀected by oxytocin in the cur-
rent study, are more related to fear. Neuroimaging stud-
ies have shown that SC and SFSC are regulated by
diﬀerent neural systems. Speciﬁcally, the medial prefrontal
cortex is involved in SC (Nagai et al., 2004), which
involves anticipatory anxiety about future punishment
(Bechara et al., 1999).
In the present study, no signiﬁcant increases in plasma
cortisol or ACTH were observed during any phase of the
experimental session. This ﬁnding agrees with recent reports
of salivary cortisol levels under very similar experimental con-
ditions, indicating that the SPST does not activate the hypo-
thalamic–pituitary–adrenal axis (Garcia-Leal et al., 2005).
Nevertheless, there are contradictory results in the litera-
ture, as some authors report no change in serum cortisol
levels (Becker et al., 1996; Lupien et al., 1997) while
others report increased cortisol following procedures simi-
lar to the SPST (Buchanan et al., 1999; Nicolson and
Van Diest, 2000).
In summary, the present results and previous reports in
experimental animals (Bale et al, 2001; McCarthy et al.,
1996; Mantella et al., 2003, 2005; Neumann et al., 2000;
Windle et al., 1997) and in humans (Heinrichs et al., 2003)
suggest that OT has anxiolytic properties.
Conclusions
The present study suggests that OT reduces anticipatory anx-
iety and the related psychophysiological measure of SC in
healthy volunteers performing public speaking. In contrast,
OT failed to aﬀect anxiety during public speaking,
Table 4. Physiological and psychophysiological changes induced by the Simulated Public Speaking Test
Heart Rate Systolic Blood Pressure Diastolic Blood Pressure Spontaneous Fluctuations (number)
Phase OT PL OT PL OT PL OT PL
Baseline 71.46 2.7 73.66 2.2 116.76 2.8 116.46 2.3 79.96 1.7 80.96 1.2 4.46 1.0 3.66 0.8
Pre-test 66.46 1.8 69.96 1.7 117.36 2.5 113.76 2.1 79.76 2.5 80.16 1.9 4.26 1.1 3.66 0.6
Anticipation 69.96 2.0 74.96 2.5 121.16 3.1 118.46 1.6 81.46 2.5 81.66 1.8 6.46 1.1 5.46 1.2
Speech 64.36 1.9 68.46 2.1 118.66 3.2 118.66 2.1 82.06 2.2 81.06 1.9 2.36 0.6 4.46 1.5
Post-test 1 63.16 1.6 68.56 2.1 115.46 2.7 114.36 2.3 80.16 2.2 80.36 1.8 1.46 0.5 2.06 0.8
Post-test 2 63.96 1.6 68.56 2.0 115.16 3.0 114.16 1.8 80.36 2.3 79.06 1.8 3.06 0.8 3.36 1.0
Data are reported as means6 SEM. OT: oxytocin, PL: placebo
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cardiovascular changes, or SFSC. Therefore, OT seems
to exert an anxiolytic action similar to that of
benzodiazepines.
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